Immortalized Cell Line Market Insights

Market Research Future (MRFR) estimated that the global immortalized cell lines market would reach the highest valuation of USD 4105.62 million, growing at a CAGR of 9.30% during the forecast period, 2015-2023.

Immortalized cell lines are non-dividing tumor cells or cells artificially engineered to proliferate indefinitely and thus can be cultured over several generations. These cell lines are expected to grow as a result of increased vaccine production and innovative technologies. In addition, the ability of cell line culture to provide more physiologically relevant information and more accurate data through in vitro testing has made cell line culture systems acceptable compared to average culture. Growing applications in biotechnology and pharmaceutical companies and hospitals, the growing number of patients in need of organ transplants, and a growing number of cancer patients are the most important factors in the growth of the market. However, the high cost of equipment and the development of a stable stem cell line, as well as the maintenance and prevention of contamination, may hinder the market growth.

Rising application of immortalized cell line culture in stem cell and cancer studies is projected to present lucrative growth opportunities to the global immortalized cell line market. Immortalized cell lines are influential tools for biological investigation and are being used in multiple research. They are also deployed to evaluate the effectiveness of anticancer drugs, which is predicted to imitate growth positively in the market over the forecast period.

Immortalized Cell Line Market Segmentation

The global immortalized cell line market is separated on the basis of method, application, and end-user.

Based on the method, the global stem cell market is segmented into virus induction, hTERT expression, tumor suppressor gene inactivation, etc.

The virus induction segment of the immortalized cell line is then divided into EBV genes, HPV-16 gene E6 / 6, SV40 T antigen, and others. The hTERT expression segment is sub-segmented into P53 and Myc T58A.

The global market for application-based immortalized cell lines is divided into the areas of diagnosis, tissue manipulation, drug development, vaccine production, and regenerative medicine, etc.

Based on the end-user, the global market is classified into pharmaceutical and biopharmaceutical companies, contract research organizations (CROs), and research laboratories. The pharmaceutical and biopharmaceutical industry represented a market value of $ 1,323.79 million in 2017.

The Americas are thought to dominate the global market for immortalized cell lines during the forecast period. This is attributed to an increase in cancer numbers, the presence of renowned pharmaceutical and biotechnology industries, increased awareness of immortalized cell lines, and substantial funding for research.

The European market for immortalized cells is expected to become the second largest in the forecast period. More government support, well-developed technology and a growing number of cancer cases are expected to spur market growth in this region.

Asia Pacific is expected to be the fastest-growing market due to rising health spending by public and private companies. In addition, the growing awareness of health care and a large number of unoperated patients has led to a growing focus of key players on expansion in this region.

Obtain Premium Research Report Details considering the impact of COVID-19 @ https://www.marketresearchfuture.com/reports/immortalized-cell-line-market-751

Immortalized Cell Line Market Players

Researchers at leading biotech companies are majorly adopting new technological advancements. Some of these key giants include Valneva, Thermo Fisher Scientific, ATCC (American Type Culture Collection Inc.), Sartorius AG, Lonza Group, Selexis, AG, Merck KGaA , SA, WuXi App Tec, European Collection of Authenticated Cell Cultures (ECACC), and Corning Incorporated.

Immortalized Cell Line Market Recent Updates

The ATCC has announced the first launch of a portfolio of exosomes, for example (extracellular vesicles) derived from human cells, intended as reference material or standards for various research applications. The first two exosomes available to researchers are derived from the A549 non-small cell lung cancer cell line and hTERT-immortalized mesenchymal stem cells.